

# Antonio Fernandez-Nebro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3814346/publications.pdf>

Version: 2024-02-01

137  
papers

7,806  
citations

109137

35  
h-index

53109

85  
g-index

148  
all docs

148  
docs citations

148  
times ranked

7119  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002, 46, 1019-1027.	6.7	1,736
2	Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. <i>Medicine (United States)</i> , 1999, 78, 167-175.	0.4	1,107
3	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.5	610
4	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. <i>Medicine (United States)</i> , 1999, 78, 167-175.	0.4	367
5	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.5	262
6	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.5	173
7	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45.	1.6	117
8	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	2.5	115
9	Osteoarticular complications of brucellosis.. <i>Annals of the Rheumatic Diseases</i> , 1991, 50, 23-26.	0.5	111
10	Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185.	1.6	101
11	The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. <i>Rheumatology</i> , 2008, 47, 1088-1092.	0.9	100
12	Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. <i>Lupus</i> , 2012, 21, 1063-1076.	0.8	98
13	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	1.4	98
14	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	2.3	97
15	BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 700-705.	0.5	96
16	Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183.	0.4	96
17	Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. <i>American Journal of Medicine</i> , 2005, 118, 552-556.	0.6	92
18	Actualizaci3n 2014 del Documento de Consenso de la Sociedad Espa3ola de Reumatolog3a sobre el uso de terapias biol3gicas en la artritis reumatoide. <i>Reumatolog3a Cl3nica</i> , 2015, 11, 279-294.	0.2	89

#	ARTICLE	IF	CITATIONS
19	HLA class II alleles associations of anticardiolipin and anti b2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Lupus</i> , 2000, 9, 47-55.	0.8	80
20	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012, 21, 4549-4557.	1.4	79
21	A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. <i>Arthritis and Rheumatism</i> , 2012, 64, 264-271.	6.7	77
22	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 454-462.	0.5	75
23	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012, 21, 926-933.	1.4	74
24	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.5	63
25	GWAS replication study confirms the association of <i>PDE3A</i> "SLCO1C1" with anti-TNF therapy response in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2013, 14, 727-734.	0.6	61
26	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2015, 54, 2042-2050.	0.9	61
27	Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-351.	0.6	57
28	HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Lupus</i> , 2003, 12, 560-563.	0.8	52
29	Long-term TNF-β Blockade in Patients with Amyloid A Amyloidosis Complicating Rheumatic Diseases. <i>American Journal of Medicine</i> , 2010, 123, 454-461.	0.6	49
30	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	0.4	48
31	Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. <i>Lupus</i> , 1999, 8, 151-157.	0.8	45
32	Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. <i>Journal of Rheumatology</i> , 2000, 27, 135-41.	1.0	45
33	Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 280.	1.6	40
34	HLA Class II DNA Typing in a Large Series of European Patients with Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2002, 81, 169-178.	0.4	39
35	Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-51.	0.6	38
36	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	1.6	37

#	ARTICLE	IF	CITATIONS
37	A functional variant of TLR10 modifies the activity of NFκB and may help predict a worse prognosis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 221.	1.6	35
38	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	1.0	34
39	Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0122088.	1.1	33
40	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	1.6	32
41	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	0.7	32
42	Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. <i>Reumatología Clínica</i> , 2013, 9, 281-296.	0.2	31
43	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	0.9	31
44	Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 2334-42.	1.0	31
45	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.5	30
46	A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 147-150.	0.9	30
47	Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 874.	1.0	30
48	Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus: Prevalence and clinical associations. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-351.	0.6	29
49	Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 43-53.	1.0	29
50	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	0.9	27
51	Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 38-45.	1.5	27
52	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. <i>Reumatología Clínica</i> , 2019, 15, 102-108.	0.2	27
53	Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 133-142.	1.0	27
54	Expansion of Rare and Harmful Lineages is Associated with Established Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1044.	1.0	26

#	ARTICLE	IF	CITATIONS
55	Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2573.	1.0	26
56	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	1.6	25
57	The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. <i>Rheumatology</i> , 2008, 47, 1732-1733.	0.9	24
58	A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 1459.	2.2	24
59	The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. <i>Genes and Immunity</i> , 2012, 13, 191-196.	2.2	23
60	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803.	0.9	23
61	Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R126.	1.6	22
62	FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	0.6	21
63	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729.	0.8	20
64	Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. <i>Journal of Rheumatology</i> , 2020, 47, 234-240.	1.0	19
65	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565.	0.8	19
66	Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. <i>Lupus</i> , 2004, 13, 934-940.	0.8	18
67	Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. <i>Rheumatology International</i> , 2017, 37, 1709-1718.	1.5	18
68	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 321-330.	1.5	17
69	Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study. <i>Reumatología Clínica</i> , 2013, 9, 18-23.	0.2	17
70	Localized rheumatoid vasculitis presenting as acute acalculous cholecystitis. <i>American Journal of Medicine</i> , 1991, 91, 90-92.	0.6	16
71	Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. <i>Lupus</i> , 2017, 26, 1407-1419.	0.8	15
72	A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1106-1111.	0.9	14

#	ARTICLE	IF	CITATIONS
73	Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2017, 19, 138.	1.6	14
74	Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the Tj ETQq0 00rgBT /Overlock 10		
75	Psoas abscess secondary to brucellosis. <i>Journal of Infection</i> , 1991, 22, 107-109.	1.7	13
76	Anti-Cofactor Autoantibodies in Systemic Lupus Erythematosus: Prevalence, Clinical and HLA Class II Associations. <i>Immunological Investigations</i> , 2008, 37, 375-385.	1.0	13
77	Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. <i>International Journal of Clinical Practice</i> , 2021, 75, e13707.	0.8	13
78	Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	12
79	Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus. <i>Reumatología Clínica</i> , 2013, 9, 359-364.	0.2	12
80	Expert recommendations on the psychological needs of patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 2167-2182.	1.5	12
81	Psychological factors associated with sleep disorders in patients with axial spondyloarthritis or psoriatic arthritis: A multicenter cross-sectional observational study. <i>Journal of Clinical Nursing</i> , 2021, 30, 266-275.	1.4	12
82	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	1.6	11
83	Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 216-224.	1.5	11
84	Postprandial Apolipoprotein B48 is Associated with Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2483.	1.0	11
85	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 281-296.	0.2	10
86	Estándares de calidad asistencial para las consultas externas de reumatología. El proyecto EXTRELLA. <i>Reumatología Clínica</i> , 2016, 12, 248-255.	0.2	10
87	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020, 59, 2043-2051.	0.9	10
88	Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study. <i>Diagnostics</i> , 2021, 11, 1794.	1.3	10
89	The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). <i>Lupus</i> , 2014, 23, 1014-1022.	0.8	9
90	Rheumatoid arthritis response to treatment across IgG1 allotype "anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Cumulative inflammatory burden and obesity as determinants of insulin resistance in patients with established rheumatoid arthritis: cross-sectional study. <i>BMJ Open</i> , 2021, 11, e044749.	0.8	9
92	Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. <i>EBioMedicine</i> , 2022, 80, 104053.	2.7	9
93	Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>Biomedicines</i> , 2022, 10, 1480.	1.4	9
94	Survival of Lupus Nephritis Patients After Renal Transplantation In Malaga. <i>Transplantation Proceedings</i> , 2012, 44, 2067-2068.	0.3	8
95	Ability to Participate in Social Activities of Rheumatoid Arthritis Patients Compared with Other Rheumatic Diseases: A Cross-Sectional Observational Study. <i>Diagnostics</i> , 2021, 11, 2258.	1.3	8
96	Análisis de la efectividad, seguridad y optimización de tocilizumab en una cohorte de pacientes con artritis reumatoide en práctica clínica. <i>Reumatología Clínica</i> , 2019, 15, 21-26.	0.2	7
97	Adiposity Is Related to Inflammatory Disease Activity in Juvenile Idiopathic Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3949.	1.0	7
98	Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. <i>Gut</i> , 2006, 55, 1666-7; author reply 1667.	6.1	7
99	Palmar fasciitis and polyarthritis syndrome is multicausal. <i>Clinical Rheumatology</i> , 1996, 15, 99-101.	1.0	6
100	Central vein thrombosis in the antiphospholipid syndrome. <i>Lupus</i> , 1997, 6, 549-551.	0.8	6
101	Quality-of-care standards for early arthritis clinics. <i>Rheumatology International</i> , 2013, 33, 2459-2472.	1.5	6
102	Identification of <i>IRX1</i> as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1384-1391.	2.9	6
103	Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Biomedicines</i> , 2022, 10, 133.	1.4	6
104	Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual. <i>Reumatología Clínica</i> , 2014, 10, 94-100.	0.2	5
105	Eficiencia de diferentes dosis de rituximab en la artritis reumatoide. <i>Reumatología Clínica</i> , 2016, 12, 139-145.	0.2	5
106	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	1.3	5
107	Genetic variation associated with cardiovascular risk in autoimmune diseases. <i>PLoS ONE</i> , 2017, 12, e0185889.	1.1	5
108	Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 927.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2437.	1.0	5
110	No evidence of association between functional polymorphisms located within <i>IL6R</i> and <i>IL6ST</i> genes and systemic sclerosis. <i>Tissue Antigens</i> , 2012, 80, 254-258.	1.0	4
111	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336.	0.9	4
112	Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 422-428.	0.2	4
113	Sarilumab monotherapy <i>vs</i> sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	0.9	4
114	Eficacia y seguridad de rituximab en neuropatía vasculárica: revisión sistemática. <i>Reumatología Clínica</i> , 2019, 15, 173-178.	0.2	4
115	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2012, 39, 1275-1279.	1.0	3
116	Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry. <i>Calcified Tissue International</i> , 2013, 93, 62-68.	1.5	3
117	Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España. <i>Reumatología Clínica</i> , 2015, 11, 144-150.	0.2	3
118	Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 102-108.	0.2	3
119	Quality Standards for Rheumatology Outpatient Clinic. The EXTRELLA Project. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 248-255.	0.2	2
120	Hospitalizaciones y mortalidad por COVID-19 en pacientes con enfermedades inflamatorias reumáticas en Andalucía. <i>Reumatología Clínica</i> , 2022, 18, 422-428.	0.2	2
121	Effectiveness, safety and economic analysis of Benepali in clinical practice. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 588-594.	0.2	2
122	Evaluation of cognitive function in adult patients with juvenile idiopathic arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 81-89.	0.9	1
123	Meningoencefalitis por <i>Cryptococcus neoformans</i> y virus varicela-zoster en paciente con lupus eritematoso sistémico. <i>Neurología</i> , 2021, 36, 719-719.	0.3	1
124	Patrones de tratamiento biológico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 años de seguimiento. <i>Reumatología Clínica</i> , 2020, 16, 447-454.	0.2	1
125	Relationship between polyautoimmunity and sarcopenic obesity in rheumatoid arthritis patients. <i>Reumatología Clínica (English Edition)</i> , 2021, . .	0.2	1
126	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. <i>Rheumatology</i> , 2022, 62, 217-224.	0.9	1



#	ARTICLE	IF	CITATIONS
127	Amiloidosis. <i>Medicine</i> , 2009, 10, 2185-2191.	0.0	0
128	Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 18-23.	0.2	0
129	Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 359-364.	0.2	0
130	FRI0424...Cardiovascular Events in Systemic Lupus Erythematosus (Sle): A Nationwide Study in Spain (Relesser Registry). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 580.2-581.	0.5	0
131	FRI0739-HPR...Expert recommendations on psychological needs of patients with rheumatoid arthritis. , 2018, , .		0
132	SAT0199...POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER).. , 2019, , .		0
133	Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 245-249.	0.2	0
134	Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España. <i>Reumatología Clínica</i> , 2021, 17, 245-249.	0.2	0
135	Meningoencephalitis caused by <i>Cryptococcus neoformans</i> and varicella-zoster virus in a patient with systemic lupus erythematosus. <i>Neurología (English Edition)</i> , 2021, 36, 719-721.	0.2	0
136	Human motion capture for movement limitation analysis using an RGB-D camera in spondyloarthritis: a validation study. <i>Medical and Biological Engineering and Computing</i> , 2021, 59, 2127-2137.	1.6	0
137	SAT0006...SIMULTANEOUS ANALYSIS OF ANTI-CCP, RHEUMATOID FACTOR, ANTI-PAD4 AND ANTI-CARBAMYLATED PROTEIN ANTIBODIES REVEALS INTERACTION EFFECTS WITH RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 933.2-934.	0.5	0